DVA

Analyst Note: DaVita Inc. (DVA)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

• Setup State: Actionable (Forming Coil)
• Breakout Level: Not yet fired.
• Current Price: $207.91.
• Extension: Not applicable (price is within the consolidation range, not extended above the breakout level).
• ATR Context: Current ATR is 2.8% (productive). This sits within the historical "sweet spot" (4–6% is ideal, but 2.8% indicates manageable volatility for a large-cap healthcare name, suggesting the setup is not yet in a high-volatility "extreme" zone).

2. Thesis Layer

• Thesis Classification: TACTICAL / Setup-Led.
• Secular Context: There is no named secular thesis attached to this specific setup at this date. The analysis must rely strictly on the quality of the price structure (the forming coil) and the immediate business fundamentals reported by management. Do not invent a macro thesis; the conviction must derive from the alignment of the setup readiness with the company's operational execution.

3. Business Overview

DaVita Inc. is a leading provider of kidney dialysis services and related laboratory services in the United States, operating in the Healthcare sector.

• Core Operations: The company provides dialysis and related lab services to patients with End-Stage Renal Disease (ESRD) or End-Stage Kidney Disease (ESKD). As of March 31, 2026, the company provided integrated care to approximately 62,600 patients in risk-based arrangements and 6,300 in other integrated care arrangements.
• Scale: As of December 31, 2025, the company served approximately 200,500 patients. The U.S. dialysis business represents approximately 86% of consolidated revenues.
• International Footprint: The international business operates 596 outpatient centers across 14 countries.
• Service Model: Beyond direct treatment, DaVita manages its own diagnostic laboratories, performs vascular access interventions, and provides administrative support to other facilities. It also furnishes acute inpatient dialysis services in approximately 850 U.S. hospitals.
• Recent Operational Performance (Q1 2026):
• Volume: Treatment per day volumes were flat in Q1 2026 compared to Q4 2025. However, total treatment volumes were ahead of expectations, driven by lower-than-expected mortality and higher patient transfers, partially offset by lower-than-expected new admissions.
• Guidance: Management raised full-year volume growth expectations from flat to a range of 25 to 50 basis points.
• Financials: Management raised adjusted operating income guidance to $2.15 billion – $2.25 billion and adjusted EPS guidance to $14.10 – $15.20 per share.
• Reimbursement: Average patient service revenue per treatment increased in Q1 2026, driven by normal annual increases in reimbursement rates, including the Medicare base rate.
• Regulatory Environment: CMS issued a final rule in November 2025 updating the Medicare ESRD PPS payment rate for 2026, estimated to increase average reimbursement for freestanding facilities by 2.2%.

4. Archetype and Conviction

• Archetype: Quality Compounder.
• Rationale: The company demonstrates consistent operational execution with management raising guidance for both volume and profitability. The business model is defensive (essential care) with a strong moat in the U.S. dialysis market. The "Quality Compounder" label fits the evidence of rising margins (operating income guidance), stable volume growth, and successful navigation of regulatory changes (CMS rate updates).
• Valuation Context: The financial spine indicates a forward consensus EPS of $14.85 for FY1 and $17.28 for FY2. The current price of $207.91 implies a forward P/E of approximately 14x for FY1 and 12x for FY2, suggesting the market is pricing in steady, moderate growth rather than hyper-growth.
• Conviction Stack:
• Thesis Strength: Moderate (Tactical, no macro tailwind named).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, 10-K/10-Q filings) confirm management's raised guidance and operational improvements.
• Setup Readiness: Partial. The price is holding above the support line, but the breakout has not fired.
• Rerating Potential: Dependent on the successful execution of the raised volume guidance and the realization of the 2.2% reimbursement increase.

5. Invalidations, Strengths, and Gaps

• Strengthening: A confirmed breakout above the resistance level (firing the coil) would confirm the setup. Continued evidence of volume growth exceeding the 25-50 bps guidance or further margin expansion would strengthen the fundamental case.
• Gaps in Evidence:
• Breakout Level: The specific price target for the breakout is not defined.
• Capex/Guidance Details: While guidance is raised, specific details on capital expenditure plans or long-term capex requirements for 2026-2027 are not explicitly detailed in the provided snippets.
• Competitive Landscape: No specific data on competitor market share shifts or new entrants is provided in the evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Management raised full-year volume growth guidance to 25-50 bps and adjusted EPS guidance to $14.10-$15.20; Q1 volumes beat expectations driven by lower mortality and higher transfers; CMS 2026 payment rule estimated to increase reimbursement by 2.2%. Key risks: New admissions remain lower than expected; mortality rates in ESKD/CKD populations rise materially; price structure fails to break out above resistance; regulatory changes beyond the 2026 rule impact reimbursement negatively. Sizing hint: Position size should reflect the "forming" nature of the setup; smaller than a confirmed breakout trade, sized to allow for the volatility of a consolidation phase. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation) and for the raised guidance to be reflected in subsequent quarterly results.